AntibioticDB

Highest development stage: Phase 1

Development status: Discontinued

Gram-positive activity

Gram-negative activity

Mechanism of Action/Target pathogen: Protein synthesis inhibitor by inhibiting methionyl tRNA synthetase; active against MRSA and Streptococcus pyrogenes. Moderately active against Gram negatives.

Reason dropped: Replidyne suspended development of this compound due to need of additional investment (S1)

GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10764

Source: https://pubmed.ncbi.nlm.nih.gov/19015366/

Citation (1): http://adis.springer.com/drugs/800025207

Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/compound/9868368

Bederocin, REP8839

Aminoacyl-tRNA synthetase inhibitor (methionyl tRNA synthetase [MetRS] inhibitor)

GSK, USA; Replidyne, Inc., (Cardiovascular Systems, Inc, USA)

2004